NCT06367673招募中1 期
Clinical Study to Evaluate the Safety and Efficacy of iPSC -NK Cells Targeting CLL1 or CD33 in Patients With Relapsed/Refractory AML
Zhejiang University1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年4月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Incidence of Treatment-Emergent Adverse Events
研究概览
简要总结
This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 or CD33 target Chimeric antigen receptor (CAR) -induced pluripotent stem cells derived NK cells in patients with relapsed/refractory AML
详细描述
Acute myelogenous leukemia (AML) is a potentially cur-able disease; 70% of newly diagnosed patients achievecomplete remission with first-line therapy, but prognosisworsens for relapsed disease in both pediatric and adultpatients.C-type lectin-like molecule-1 and cluster of differentiation antigen 33 has attracted the researchers' attention due to its high expression in AML while being absent in normal hematopoietic stem cell. Accumulating evidence have demonstrated CLL-1 or CD33 is an ideal target for AML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years old.
- •Confirmed diagnosis of r/r AML
- •CLL1 or CD33 expression is positive in AML blasts.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and life expectancy greater than 12 weeks.
- •Adequate organ and marrow function, as defined below:
- •Blood creatinine (Cr) ≤ 2 x ULN or calculated creatinine clearance (Cockcroft- Gault formula) ≥ 50 mL/min;
- •Total bilirubin (TBIL) ≤ 2 x the ULN;
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN;
- •International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN 6.Females of childbearing potential must have a negative serum pregnancy test. 7.Donor specific antibody (DSA) is negative: MFI <=
- •8.Provision of signed and dated informed consent form (ICF).
排除标准
- •Allergic to drug used in this study.
- •Subjects received any antitumor therapy as follows, prior to first NK infusion:
- •a. Systemic steroid therapy within 3 days (except physiological replacement therapy):b. Systemic antitumor therapy within 2 weeks or at least 5 half-lives, whichever is less; c. Radiotherapy within 4 weeks; d. Donor lmphocyte infusion within 6 weeks: e. Intrathecal treatment within 1 week; f CAR-T therapy, CAR-NK therapy, or any other genetically modified cell therapy product within 6 months;
- •History of allogeneic stem cell transplantation.
- •Received the vaccine within 4 weeks pror to the first infusion andor expected to reuire vaccination from the study period to 12 weeks ater the last intusion
- •Active central nervous system Leukemia.
- •Acute Promyelocytic Leukemia (APL).
- •.History of other malicnant tumors, except for those who have achieved omplete remission more than 5 years after radical treatment without any sions of recurence
- •History of central nervous system disease or meningeal involvement such as epilepsy, paralysis, aphasia, stroke, etc
- •Active autoimmune diseases.
- •Serious cardiovascular and cerebrovascular diseases:a. Severe heart rhythm or conduction abnormalities, corrected OT interval (OTc)>480 ms:h, Aute coronay sndrome conestve heat faur. aortic disection-stroke. or other orade 3 or hioher ardiovasular and cerebrovascular events within 6 months orior to firstinfusiorC, New York Heart Association (NYHA) class l or above congestive heart failure or left ventricular eiection fraction (LVEF <50% in olor Doppler echocardiography,d. Hypertension that cannot be controlled by drug.
- •Active pulmonary infection: Sp02 90%: Pulmonary embolism, chronic obstructive pulmonary disease, or interstitial lung disease
- •Uncontrolled bacterial, fungal, or viral infection.Known HlV infection, active Hepatitis B (HBV) or Hepatitis C (HCV) infection
- •Historv of substance abuse.
- •Toxicity induced by previous therapy not recovered to s grade 2(NCI-CTCAE 5.0).
- •Large suraical treatment within 4 weeks prior to first infusion, not including diagnostic biopsy.
- •Pregnant/breastfeeding women.
- •nvestigator-assessed presence of any medical or social issue that are likely to interfere with study conduct or may cause increased risk to subiect
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events
时间窗: 28 Days from first dose of iPSC NK cell infusion
Safety and Tolerability
次要结局
未报告次要终点
研究者
He Huang
Professor
Zhejiang University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid LeukemiaAML, AdultNCT06027853Zhejiang University24
已完成
1 期
Natural Killer(NK) Cell Therapy in Acute Myeloid LeukemiaAML, AdultMinimal Residual DiseaseNCT05987696Institute of Hematology & Blood Diseases Hospital, China2
已完成
1 期
A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant NeoplasmAdvanced TumorsNCT05429008Hutchmed40
终止
1 期
A Study of AZD0466 in Patients With Advanced Hematologic or Solid TumorsAdvanced Solid TumorsHematologic MalignanciesMultiple MyelomaLymphomaNCT04214093AstraZeneca9
Enrolling By Invitation
1 期
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid TumorsNCT06115642Shanghai Henlius Biotech367